Clinical trial
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Study timeline
Study start (actual)2024-06-11Date precision: day
Registry last updated2026-08-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Anatomic Stage I Breast Cancerunresolved
Anatomic Stage II Breast Cancerunresolved
Anatomic Stage III Breast Cancerunresolved
Invasive Breast Lobular Carcinomaunresolved
Interventions
Endocrine TherapyPROCEDURE
Biopsy of breastPROCEDURE
NeratinibDRUG · verified · RxNorm: neratinib
Biospecimen CollectionPROCEDURE
MammogramPROCEDURE
Magnetic Resonance ImagingPROCEDURE
Breast SurgeryPROCEDURE
UltrasoundPROCEDURE
Sponsors & collaborators
Vanderbilt-Ingram Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
Puma Biotechnology, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05919108 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.